



FINANCIAL TEAR SHEET

Corporate Profile


Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Stock Information

JNCE (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$7.45
Change (%)	▼ 0.01 (0.13%)
Volume	65,074
52 Week Low	\$6.56
Market Cap	\$243,402,105
Rolling EPS	-0.96
PE Ratio	0
Shares Outstanding	32,627,628

Data as of 08/16/18 1:08 p.m. ET



Recent Headlines & Events

08/09/18 - 6:30 a.m.

Jounce Therapeutics Reports Second Quarter 2018 Financial Results

08/02/18 - 8:00 a.m.

Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

06/02/18 - 4:00 p.m.

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
08/15/18	4
08/15/18	4
08/15/18	4
08/09/18	10-Q

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.